原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展

doi:10.3969/j.issn.1004-583X.2024.01.016

摘要/Abstract

摘要：

自身免疫性肝病主要包括自身免疫性肝炎(autoimmune hepatitis,AIH)、原发性胆汁性胆管炎(primary biliary cholangitis,PBC)、原发性硬化性胆管炎。临床上部分患者出现两种或两种以上自身免疫性肝病的临床、生化及病理特征,称为重叠综合征,其中PBC-AIH重叠综合征最常见。与独立诊断的PBC或AIH患者相比,PBC-AIH重叠综合征的肝脏相关不良事件发生率更高,疾病进展速度更快,预后更差。本文就PBC-AIH重叠综合征的诊治进展作一综述,以期提高临床医师对该病的认识。

关键词: 肝炎,自身免疫性, 胆管炎, 诊断, 治疗

中图分类号:

R575.1

游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2024.01.016

https://www.lchc.cn/CN/Y2024/V39/I1/84

参考文献 38

[1]	Montano-Loza AJ, Allegretti JR, Cheung A, et al. Single topic conference on autoimmune liver disease from the Canadian Association for the study of the liver[J]. Can Liver J, 2021, 4(4): 401-425. doi: 10.3138/canlivj-2021-0006 URL
[2]	The Committee of the Autoantibodies Detection of Rheumatology and Immunology Physicians Committee of Chinese Medical Doctor Association. Expert consensus on clinical application of autoantibodies detection in patients with autoimmune liver disease[J]. Chin J Intern Med, 2021, 60(7): 619-625.
[3]	中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(3): 264-275.
[4]	Schulz L, Sebode M, Weidemann SA, et al. Variant syndromes of primary biliary cholangitis[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35:55-61. doi: S1521-6918(18)30027-1 pmid: 30343711
[5]	Li Z, Liu Y, Yang F, et al. Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Biomed Res Int, 2020, 2020:1934541.
[6]	To U, Silveira M. Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 603-611. doi: S1089-3261(18)30035-7 pmid: 30259856
[7]	Yan YL, Xing X, Wang Y, et al. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome[J]. World J Gastroenterol, 2022, 28(18): 2021-2033. doi: 10.3748/wjg.v28.i18.2021 URL
[8]	European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi: S0168-8278(17)30186-1 pmid: 28427765
[9]	Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28(2):296-301. doi: 10.1002/hep.510280203 pmid: 9695990
[10]	倪萍, 凡小丽, 杨丽. 自身免疫性肝病重叠综合征的研究现状[J]. 临床肝胆病杂志, 2020, 36(4): 743-748.
[11]	Kuiper EM, Zondervan PE, Van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome[J]. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534. doi: 10.1016/j.cgh.2010.03.004 URL
[12]	Liu F, Pan ZG, Ye J, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Simplified criteria may be effective in the diagnosis in Chinese patients[J]. J Dig Dis, 2014, 15(12): 660-668. doi: 10.1111/cdd.2014.15.issue-12 URL
[13]	张骏飞, 许何明, 宋海燕, 等. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征:巴黎标准诊断中国患者灵敏度低[J]. 实用肝脏病杂志, 2019, 22(4): 537-540.
[14]	杨宁, 刘雁声, 韩英. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治[J]. 临床肝胆病杂志, 2020, 36(3): 697-700.
[15]	Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. doi: 10.1016/j.jhep.2010.09.002 pmid: 21067838
[16]	Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5):929-538. doi: 10.1016/s0168-8278(99)80297-9 pmid: 10580593
[17]	Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. doi: 10.1002/hep.22322 pmid: 18537184
[18]	Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: A simplified scoring system may assist in the diagnosis[J]. Am J Gastroenterol, 2010, 105(2): 345-353. doi: 10.1038/ajg.2009.616 pmid: 19888204
[19]	Zhang W, De D, Mohammed KA, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Hepatol Commun, 2018, 2(3): 245-253. doi: 10.1002/hep4.1148 pmid: 29507900
[20]	Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. doi: S0168-8278(19)30228-4 pmid: 30980847
[21]	Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115(2): 262-270. doi: 10.14309/ajg.0000000000000512 pmid: 31985529
[22]	中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(5): 482-492.
[23]	Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. doi: 10.1111/cdd.2019.20.issue-7 URL
[24]	王绮夏, 马雄. 自身免疫性肝病重叠综合征诊治进展[J]. 胃肠病学, 2018, 23(5): 283-286.
[25]	张晓梅. 熊去氧胆酸单药治疗原发性胆汁性肝硬化肝炎重叠综合征的临床研究[J]. 现代消化及介入诊疗, 2017, 22(4): 487-489.
[26]	郭丽萍, 周璐, 李树倩, 等. 熊去氧胆酸单药或联合免疫抑制剂治疗原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征的疗效分析[J]. 中华消化杂志, 2016, 36(3): 155-160.
[27]	Chazouillères O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406. doi: 10.1016/j.jhep.2005.10.017 pmid: 16356577
[28]	Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2014, 12(5): 863-869. doi: 10.1016/j.cgh.2013.09.021 URL
[29]	Fan X, Zhu Y, Men R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: A real-world study[J]. Can J Gastroenterol Hepatol, 2018, 2018: 1965492.
[30]	Freedman BL, Danford CJ, Patwardhan V, et al. Treatment of overlap syndromes in autoimmune liver disease: A systematic review and meta-analysis[J]. J Clin Med, 2020, 9(5): 1449.
[31]	Baven-Pronk AM, Coenraad MJ, Van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther, 2011, 34(3): 335-343. doi: 10.1111/apt.2011.34.issue-3 URL
[32]	Efe C, Hagström H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. doi: 10.1016/j.cgh.2017.06.001 URL
[33]	Hanouneh M, Ritchie MM, Ascha M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. doi: 10.1080/00365521.2018.1551498 URL
[34]	Faisal N, Renner EL. Recurrence of autoimmune liver diseases after liver transplantation[J]. World J Hepatol, 2015, 7(29): 2896-2905. doi: 10.4254/wjh.v7.i29.2896 pmid: 26689244
[35]	Liberal R, Zen Y, Mieli-Vergani G, et al. Liver transplantation and autoimmune liver diseases[J]. Liver Transpl, 2013, 19(10): 1065-1077. doi: 10.1002/lt.v19.10 URL
[36]	Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes[J]. Am J Gastroenterol, 2007, 102(6): 1244-1250. pmid: 17319931
[37]	Park Y, Cho Y, Cho EJ, et al. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: Characteristics, treatments, and outcomes[J]. Clin Mol Hepatol, 2015, 21(2): 150-157. doi: 10.3350/cmh.2015.21.2.150 pmid: 26157752
[38]	Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2016, 50(1): 114-123. doi: 10.1007/s12016-015-8516-5 URL

原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏宁宁, 吴以龙, 杨沱, 林钦棋, 林卫星, 林敏. 胆道子镜辅助内镜逆行阑尾炎治疗术治疗急慢性阑尾炎27例临床分析[J]. 临床荟萃, 2026, 41(7): 596-601.
[2]	朱洪银, 严丹, 肖志原, 杨盼. 大剂量普瑞巴林中毒的临床救治与转归1例[J]. 临床荟萃, 2026, 41(7): 642-647.
[3]	张天娇, 宋菲, 由佳鹭, 金雨佳, 孙妍. 肝癌细胞上皮-间质转化中微小RNA通路调控的研究进展[J]. 临床荟萃, 2026, 41(7): 659-667.
[4]	欧阳芊, 赵颖, 孟珩, 徐安定. 缺血性卒中急性期的抗血小板治疗[J]. 临床荟萃, 2026, 41(6): 485-492.
[5]	张艳丽, 赵朕华, 张敬知, 孟庆顺. 抗整合素抗体αvβ6在溃疡性结肠炎诊断中的应用[J]. 临床荟萃, 2026, 41(6): 568-571.
[6]	周颖, 周芳芳. 急性肾损伤新型生物标志物的研究进展[J]. 临床荟萃, 2026, 41(5): 475-480.
[7]	李鑫月, 李世豪, 刘娜, 吴婧, 李美玲, 刘改芳. CC趋化因子配体调控胃癌的研究现状及进展[J]. 临床荟萃, 2026, 41(4): 363-368.
[8]	刘一坤, 张明, 刘倩, 孙绍婷, 李媛媛, 杜书同. 连续性肾脏替代治疗在脓毒症合并急性肾损伤中的研究进展[J]. 临床荟萃, 2026, 41(4): 374-379.
[9]	姜俊辰, 郭蓉娟, 张帆, 刘佳霖. MAPK信号通路在脑出血中的研究进展[J]. 临床荟萃, 2026, 41(3): 269-273.
[10]	刘栋, 杨启昌, 李欣然. 抑郁症与肠道菌群关联性的研究进展及趋势分析[J]. 临床荟萃, 2026, 41(3): 285-288.
[11]	张艳萍, 李坷, 张壮. 心房颤动相关急性脑梗死早期启动抗凝治疗的安全性[J]. 临床荟萃, 2026, 41(2): 116-121.
[12]	河北医科大学第二医院神经外科癫痫亚专业组人工智能诊断模型辅助癫痫脑电图诊断专家共识工作组. 人工智能诊断模型辅助癫痫脑电图诊断专家共识[J]. 临床荟萃, 2026, 41(2): 164-168.
[13]	郝清卿, 张飞飞, 吕仕林. 单纯药物涂层球囊在冠状动脉介入治疗中的研究进展[J]. 临床荟萃, 2026, 41(2): 188-192.
[14]	孙振晓, 张继香. 音乐强迫性障碍1例并文献复习[J]. 临床荟萃, 2026, 41(1): 64-67.
[15]	潘炎, 严晓华, 焦富勇. 川崎病流行病学现状、争议及展望[J]. 临床荟萃, 2025, 40(9): 861-864.